Second Edition Textbook, ‘Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease,’ Provides Roadmap for Preclinical and Clinical Research

A timely analysis of different approaches to developing metabolic therapies, with insights from world-renowned experts in clinical drug development

SAN DIEGO, April 10, 2019 /PRNewswire/ – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on metabolic diseases, announced today the second edition textbook, Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease, edited by Andrew Krentz, MD, Christian Weyer, MD, and Marcus Hompesch, MD. The textbook is published by Springer International, a leading global scientific publisher.

Following the success of the first edition, this widely sourced textbook provides a detailed overview of current and emerging translational research methods and regulatory considerations for diabetes, obesity, and nonalcoholic steatohepatitis (NASH), representing leading-edge knowledge in drug development for metabolic diseases.

The textbook has expanded its coverage of metabolism-related translational research topics with special consideration given to the drug discovery process and cardiovascular research methods. Most notably, translational methods for NAFLD/NASH, a rapidly expanding area of research, are discussed extensively in this edition. The textbook provides an in-depth analysis of methods to assess insulin sensitivity, insulin secretion, metabolic flux, thermogenesis and metabolomics for a spectrum of metabolic diseases, as well as emerging non-invasive imaging methods and circulating biomarkers to assess treatment response in early phase NASH trials. 

“The chapters in this book provide important contributions to our knowledge on the scientific and regulatory issues related to metabolic drug development, focusing on early clinical proof of mechanism, early stage indicators of drug efficacy, biomarkers and safety and providing a critical analysis of cutting-edge translational research methodologies,” said Jerrold M. Olefsky, MD, University of California, San Diego, Professor of Medicine and Associate Dean for Scientific Affairs. “This textbook will be a valuable resource to anyone in the field of metabolic clinical research, as well as clinicians practicing in these specialties.” 

Authors include leading experts in academic research and drug development from ProSciento; Antaros Medical; Merck & Co.; Owl Metabolomics; Gubra; Flux Biosciences; Helmholtz Zentrum München; Kinexum, Inc.; Maastricht University Medical Centre; University of Leeds; University of Copenhagen; University of California, San Diego; University of California, Berkeley, University of Florida, Orlando, and University of Florida, Gainesville. A list of chapters and authors is available on the Springer website.

The textbook is available in hardcover and electronic formats, and individual chapters can be downloaded at, and other textbook distributors.

About ProSciento, Inc.
ProSciento is a leading specialized clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally. For more information, please visit

For inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.

Carine Beysen, DPhil
Senior Director, Clinical Research Innovation, ProSciento, Inc.